Welcome to our dedicated page for Integra Lifesciences Hldgs Cp news (Ticker: IART), a resource for investors and traders seeking the latest updates and insights on Integra Lifesciences Hldgs Cp stock.
Integra Lifesciences Holdings Corp (IART) delivers innovative medical solutions for neurosurgery, orthopedic care, and tissue regeneration. This dedicated news hub provides investors and healthcare professionals with essential updates on the company’s advancements in surgical technology and patient care.
Access consolidated information on FDA clearances, product innovations, and strategic partnerships that shape modern surgical practices. Our repository includes earnings reports, regulatory milestones, and leadership updates critical for understanding IART’s market position.
Key content categories cover developments in Codman Specialty Surgical instruments, Tissue Technologies advancements, and operational updates from global manufacturing facilities. Stay informed about technologies enhancing neurosurgical monitoring and extremity repair solutions.
Bookmark this page for streamlined access to Integra’s verified press releases and analysis. Check regularly for updates driving progress in surgical precision and regenerative medicine across 100+ countries.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) reported first quarter 2023 revenues of $380.8 million, marking a 1.1% increase year-over-year on a reported basis and 4.6% growth organically. GAAP earnings per diluted share were $0.29, down from $0.39 in the previous year, with adjusted earnings remaining steady at $0.74. The company reaffirmed its full-year revenue guidance of $1,602 to $1,620 million and adjusted EPS guidance of $3.43 to $3.51. Segment performance showed $248.1 million in revenues from Codman Specialty Surgical, while Tissue Technologies generated $132.7 million. Key highlights include strong demand across product lines and a successful launch of new products. The company also strengthened its balance sheet and returned value to shareholders through a $150 million share repurchase program.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) will announce its first quarter 2023 financial results on April 26, 2023, before market opening. A conference call will follow at 8:30 a.m. ET to discuss the earnings.
Investors can access the live webcast on the company's investor website. A replay of the call will be available afterward. Integra is renowned for its regenerative tissue technologies and neurosurgical solutions, providing high-quality products that support optimal patient care.